Kite en­lists Epic Bio to ap­ply epi­ge­net­ic edit­ing in cre­at­ing next-gen CAR-T cells

Kite, the Gilead sub­sidiary spe­cial­iz­ing in CAR-T, is try­ing out epi­ge­net­ic edit­ing as it seeks new ways to cre­ate next-gen­er­a­tion cell ther­a­pies that are more ef­fec­tive against can­cer.

Team­ing up with Cal­i­for­nia-based Epic Bio, Kite will tap its new part­ner’s tech­nol­o­gy to en­gi­neer T cells by tin­ker­ing with gene ex­pres­sion — in hopes of “in essence, over­com­ing more than one tu­mor chal­lenge with one tech­nol­o­gy,” said David Bar­rett, Kite’s vice pres­i­dent of cell bi­ol­o­gy and trans­la­tion­al med­i­cine.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER